338 reports of this reaction
1.7% of all ASENAPINE MALEATE reports
#19 most reported adverse reaction
HYPOAESTHESIA ORAL is the #19 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 338 FDA adverse event reports linking ASENAPINE MALEATE to HYPOAESTHESIA ORAL. This represents approximately 1.7% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience hypoaesthesia oral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOAESTHESIA ORAL is a less commonly reported adverse event for ASENAPINE MALEATE, but still significant enough to appear in the safety profile.
In addition to hypoaesthesia oral, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to hypoaesthesia oral in FDA adverse event reports:
HYPOAESTHESIA ORAL has been reported as an adverse event in 338 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOAESTHESIA ORAL accounts for approximately 1.7% of all adverse event reports for ASENAPINE MALEATE, making it a notable side effect.
If you experience hypoaesthesia oral while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.